Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE-J
NCT06010004Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orforglipron in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Sep 2023; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06010004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06010004.